RT Journal Article
SR Electronic
T1 Retrospective Analysis of Trabectedin Therapy for Soft Tissue Sarcoma
JF In Vivo
JO In Vivo
FD International Institute of Anticancer Research
SP 1609
OP 1614
DO 10.21873/invivo.11644
VO 33
IS 5
A1 KUNIKI KAWAGUCHI
A1 KENJI NAKANO
A1 TETSUYA URASAKI
A1 NAOKI FUKUDA
A1 SHINICHIRO TAIRA
A1 MAKIKO ONO
A1 JUNICHI TOMOMATSU
A1 MASATOSHI NISHIZAWA
A1 KEISUKE AE
A1 SEIICHI MATSUMOTO
A1 SHUNJI TAKAHASHI
YR 2019
UL http://iv.iiarjournals.org/content/33/5/1609.abstract
AB Background/Aim: Trabectedin is a synthetic antineoplastic agent approved for advanced soft tissue sarcoma (STS) in Japan. The aim of this study was to evaluate the efficacy and safety of the Japan-approved dose of trabectedin for advanced STS. Patients and Methods: We retrospectively reviewed 38 patients with advanced STS who received salvage chemotherapy with trabectedin. Results: The overall response and disease control rates were 16% (5 patients) and 67% (20 patients), respectively. The median progression-free and overall survival were 7.3 and 17.8 months, respectively. There were no significant differences between patients with liposarcoma or leiomyosarcoma and those without, or between patients with TRS and those without. The most common grade 3-4 AEs were elevated transaminases and neutropenia. Conclusion: Trabectedin 1.2 mg/m2, as the approved dose in Japan, showed similar efficacy to the dose of 1.5 mg/m2 used in Western countries. Trabectedin could be an option for advanced STS in Japan, regardless of histological subtype.